Global Functional Bowel Disorder Agents Market – Industry Trends and Forecast to 2029

Global Functional Bowel Disorder Agents Market, By Drug Class (Anticholinergics, Chloride Channel Activators, Guanylate Cyclase-C Agonists, NHE3 Inhibitors, Peripheral Opioid Receptor Antagonists, Peripheral Opioid Receptor Mixed Agonists/Antagonists, Serotoninergic Neuroenteric Modulators), Application (Irritable Bowel Syndrome, Chronic Bloating, Diarrhea, Constipation, Others), Dosage (Injection, Tablet, Others), Route of Administration (Oral, Intravenous, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029

Market Analysis and Size

In recent years, the functional bowel disorder agents? market is anticipated to grow rapidly during the forecast period. According to the United Nations' World Population Ageing Highlight 2020 study, the worldwide geriatric population is forecast to rise from 727 million in 2020 to 1.5 billion by 2050, a nearly two-fold increase, while the share of the geriatric population in 2020 was about 9.3%, and is expected to rise to 16% by 2050. Geriatric population are at the high risk of functional bowel disorders. This lead to the high demand of functional bowel disorder agents in the healthcare sector.

Data Bridge Market Research analyses that the functional bowel disorder agents? market was valued at USD 2.071 billion in 2021 and is expected to reach USD 3.25 billion by 2029, registering a CAGR of 5.80% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Irritable bowel syndrome, chronic bloating, diarrhoea, and constipation are all treated with functional bowel disorder medicines, which work in different ways to ease symptoms. Chronic gastrointestinal (GI) symptoms (such as stomach pain, dysphagia, dyspepsia, diarrhoea, constipation, and bloating) in the lack of pathology on traditional tests characterize functional gastrointestinal disorders (FGID).

Report Scope and Market Segmentation

Functional Bowel Disorder Agents? Market Dynamics

Drivers

• Increasing incidences of functional gastrointestinal disorders (FGIDs)

The rising incidences of functional gastrointestinal disorders (FGIDs) is anticipated to influence the functional bowel disorder agents? market's growth. Growing smoking addiction and sedentary lifestyle of people are some of the causes of FGIDs.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of functional bowel disorder agents? market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the functional bowel disorder agents? market. Additionally, high disposable income and increasing cases of stress and depression will result in the expansion of functional bowel disorder agents? market. Along with this, rising geriatric population and favourable reimbursement policies will enhance the growth rate of the market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the functional bowel disorder agents? market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the functional bowel disorder agents? market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the drug development and distribution? will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the functional bowel disorder agents? market. Additionally, side effects of functional bowel disorder agents? and lack of awareness will act as market restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This functional bowel disorder agents? market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the functional bowel disorder agents? market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

functional gastrointestinal disorders (FGIDs) are quite frequent, with a global incidence of 40%. They are more common in women than in males, and their prevalence diminishes with age. They are responsible for 12% of primary care burden and 30% of gastrointestinal outpatient consultations. More over two-thirds of FGID patients will have seen a doctor in the previous year, and 40% will take regular medication. This increases the use of functional bowel disorder agents.

Functional bowel disorder agents? market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Functional Bowel Disorder Agents? Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. This can be ascribed to severe disruptions in their respective manufacturing and supply-chain operations therefore as consequence of multiple precautionary lockdowns and other limitations imposed by governments all over the world. The functional bowel disorder agents market is no exception. Furthermore, consumer preferences has decreased as people are now much more concentrated on removing non-essential expenses from their budgets as the wider economic situation of most people has been adversely impacted by this outbreak. Over the forecast period, the aforementioned factors are likely to have a negative impact on the functional bowel disorder agents market's revenue trajectory.

Global Functional Bowel Disorder Agents? Market Scope

The functional bowel disorder agents? market is segmented on the basis of drug class, application, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Anticholinergics
• Chloride Channel Activators
• Guanylate Cyclase-C Agonists
• NHE3 Inhibitors
• Peripheral Opioid Receptor Antagonists
• Peripheral Opioid Receptor Mixed Agonists/Antagonists
• Serotoninergic Neuroenteric Modulators

On the basis of drug class, the global hepatic drugs market is segmented into anticholinergics, chloride channel activators, guanylate cyclase-C agonists, NHE3 inhibitors, peripheral opioid receptor antagonists, peripheral opioid receptor mixed agonists/antagonists, and serotoninergic neuroenteric modulators.

Application

• Irritable Bowel Syndrome
• Chronic Bloating
• Diarrhea
• Constipation
• Others

On the basis of application, the global hepatic drugs market is segmented into irritable bowel syndrome, chronic bloating, diarrhea, constipation and others.

Dosage

• Injection
• Tablet
• Others

On the basis of dosage, the functional bowel disorder agents? market is segmented into injection, tablet and others.  

Route of Administration

• Intravenous
• Oral
• Others

The route of administration segment for the functional bowel disorder agents? market is segmented into intravenous, oral and others.

 End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

On the basis of end-users, the functional bowel disorder agents? market is segmented into hospitals, specialty clinics, homecare and others.

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

On the basis of distribution channel, the functional bowel disorder agents? market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.

Functional Bowel Disorder Agents Market Regional Analysis/Insights

The Functional bowel disorder agents? market is analysed and market size insights and trends are provided by country, drug class, application, dosage, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Functional bowel disorder agents? market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the functional bowel disorder agents? market because of the well-established healthcare sector in this region. Additionally, growing presence of major key players will further propel the market’s growth rate in this region.

Asia-Pacific are expected to grow during the forecast period due to rising healthcare expenditure and improvements in healthcare infrastructure in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Functional Bowel Disorder Agents? Market Share Analysis

The Functional bowel disorder agents? market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to functional bowel disorder agents? market.

Some of the major players operating in the functional bowel disorder agents? market are:

• Abbott (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (US)
• Teva Pharmaceutical Industries Ltd.( Israel)
• Sanofi (France)
• Novartis AG (Switzerland)
• Sun Pharmaceutical Industries Ltd. (India)
• Takeda Pharmaceutical Company Limited (Japan)
• Pfizer Inc. (US)
• GlaxoSmithKline plc (UK)
• AstraZeneca (UK)
• Johnson & Johnson Private Limited (US)
• Boehringer Ingelheim International GmbH. (Germany)
• Astellas Pharma Inc. (Japan)
• Allergan (Ireland)
• Mitsubishi Tanabe Pharma Corporation (Japan)
• Kyowa Kirin Co., Ltd.(Japan)
• Liminal BioSciences Inc. (Canada)
• Avexegen Therapeutics, Inc.(US)
• AbbVie Inc. (US)